Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?

被引:1
作者
Kurtaran, Amir [1 ,2 ]
Schmoll-Hauer, Brigitte [1 ,2 ]
Tugendsam, Christina [1 ,2 ]
机构
[1] Krankenanstalt Rudolfstiftung Wien, Nukl Med PET CT & Schilddrusen Kompetenzzentrum, Nukl Med Inst, Juchgasse 25, A-1030 Vienna, Austria
[2] Sigmund Freud Privatuniv, Vienna, Austria
关键词
Differentiated thyroid carcinoma; Individualized treatment; Risk stratification; Radioablation; Active surveillance; RADIOACTIVE IODINE THERAPY; RANDOMIZED CLINICAL-TRIAL; REMNANT ABLATION; PAPILLARY MICROCARCINOMA; SERUM THYROGLOBULIN; ASSOCIATION GUIDELINES; POSTOPERATIVE ABLATION; SUPPRESSION THERAPY; RADIOIODINE THERAPY; ENDOCRINE SURGEONS;
D O I
10.1007/s10354-019-00713-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In recent years, there has been worldwide a significant (relative) increase in "small" thyroid cancer (pT1= tumor size of <= 10mm), which has now reached a plateau. This fact and the absence of prospective and randomized clinical trials are increasingly leading to a discussion of the so-called risk-adapted management of differentiated thyroid cancer. The available studies are partly incomplete, retrospective and difficult to compare. In addition, factors such as different iodine supply, cost-benefit considerations and regional differences in quality of surgical procedures influence the implementation of therapy concepts. Therefore, the therapy of the differentiated thyroid cancer is currently the subject of intensive discussion, especially in "low risk" situations. There is a worldwide trend to classify the risk of differentiated thyroid cancer in general lower than in the past and thus also to reduce the extent of the traditionally recommended therapy. The discussion is increasingly moving from the "one size fits all" towards personalized and thus risk-adapted therapy of the differentiated thyroid cancer. The main goal of this "paradigm shift" is to avoid an "overtreatment" which may be associated with permanent complications due to "unnecessary" surgical procedures and any negative effects of radioiodine ablation. This overview attempts to answer the following questions: When is a risk-adapted therapy for differentiated thyroid cancer justified? What are the consequences in differentiated thyroid cancer if no radioiodine therapy is performed?
引用
收藏
页码:15 / 25
页数:11
相关论文
共 83 条
[21]   Cardiovascular Disease and Thyroid Function [J].
Faber, Jens ;
Selmer, Christian .
CARDIOVASCULAR ISSUES IN ENDOCRINOLOGY, 2014, 43 :45-+
[22]   Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial [J].
Fallahi, Babak ;
Beiki, Davood ;
Takavar, Abbas ;
Fard-Esfahani, Armaghan ;
Gilani, Kianoush Ansari ;
Saghari, Mohsen ;
Eftekhari, Mohammad .
NUCLEAR MEDICINE COMMUNICATIONS, 2012, 33 (03) :275-282
[23]   Are posttherapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? [J].
Fatourechi, V ;
Hay, ID ;
Mullan, BP ;
Wiseman, GA ;
Eghbali-Fatourechi, GZ ;
Thorson, LM ;
Gorman, CA .
THYROID, 2000, 10 (07) :573-577
[24]   Independent predictors and lymph node metastasis characteristics of multifocal papillary thyroid cancer [J].
Li Genpeng ;
Lei Jianyong ;
You Jiaying ;
Jiang Ke ;
Li Zhihui ;
Gong Rixiang ;
Zhang Lihan ;
Zhu Jingqiang .
MEDICINE, 2018, 97 (05)
[25]   Radioiodine Treatment of Well-Differentiated Thyroid Cancer: Balancing Risks and Benefits [J].
Greenspan, Bennett S. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18) :1785-+
[26]  
Groopman J., 2011, Your medical mind, How to decide what is right for you
[27]   Increase of papillary thyroid microcarcinoma and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients [J].
Gschwandtner, Elisabeth ;
Klatte, Tobias ;
Swietek, Natalia ;
Bures, Claudia ;
Kober, Friedrich ;
Ott, Johannes ;
Schultheis, Andrea ;
Neuhold, Nikolaus ;
Hermann, Michael .
SURGERY, 2016, 159 (02) :503-511
[28]   2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer [J].
Haugen, Bryan R. ;
Alexander, Erik K. ;
Bible, Keith C. ;
Doherty, Gerard M. ;
Mandel, Susan J. ;
Nikiforov, Yuri E. ;
Pacini, Furio ;
Randolph, Gregory W. ;
Sawka, Anna M. ;
Schlumberger, Martin ;
Schuff, Kathryn G. ;
Sherman, Steven I. ;
Sosa, Julie Ann ;
Steward, David L. ;
Tuttle, R. Michael ;
Wartofsky, Leonard .
THYROID, 2016, 26 (01) :1-133
[29]   Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients [J].
Hay, ID ;
Thompson, GB ;
Grant, CS ;
Bergstralh, EJ ;
Dvorak, CE ;
Gorman, CA ;
Maurer, MS ;
McIver, B ;
Mullan, BP ;
Oberg, AL ;
Powell, CC ;
van Heerden, JA ;
Goellner, JR .
WORLD JOURNAL OF SURGERY, 2002, 26 (08) :879-885
[30]   Incidence of Nonthyroidal Primary Malignancy and the Association with 131I Treatment in Patients with Differentiated Thyroid Cancer [J].
Hirsch, Dania ;
Shohat, Tzippy ;
Gorshtein, Alex ;
Robenshtok, Eyal ;
Shimon, Ilan ;
Benbassat, Carlos .
THYROID, 2016, 26 (08) :1110-1116